(59 days)
The Clear Tip is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum).
The ClearTip is a manually operated endoscopic instrument intended to obtain tissue specimens of gastrointestinal tract (=digestive tract) and tracheobronchial tree. The subject device mainly consists of a handle unit with an insertion part, a syringe, a stopcock, and a connector. This device passes through a working channel of an endoscope, and the average contact time with the submucosal or external lesions of a gastrointestinal tract or a tracheobronchial tree is less than 1 hour. This device is supplied sterile for single-patient use and shall be not reused or resterilized.
The provided document does not contain information regarding the acceptance criteria of a study that proves the device meets specific performance metrics. It's a 510(k) summary for a medical device (ClearTip) seeking substantial equivalence to predicate devices, not a study report demonstrating specific performance against acceptance criteria.
The document discusses substantial equivalence based on:
- Indications for Use: The ClearTip is intended for Ultrasonically Guided Fine Needle Aspiration (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract.
- Comparison to Predicate Devices: The document provides a detailed comparison table between the subject device (ClearTip) and two predicate devices (SonoTip Pro and Pro Flex EBUS-TBNA Needle System, and Clear-Tip EUS-FNA) regarding various characteristics like device name, classification, product code, regulation number, indications for use, needle gauge, material, length, sheath material, accessory channel diameter, endoscope compatibility, use with syringe/stopcock, principle of operation, shelf life, sterility, and single use.
- Non-clinical Tests: The following tests were performed on the subject device to support substantial equivalence: Sterilization Validation Test, Shelf-Life Test, Appearance, Dimensions, Operability, Elasticity, Bending Strength, Pull-out, Tensile Force, and Biocompatibility Tests. The document states that the test results support the device's substantial equivalence but does not provide specific acceptance criteria or reported performance values for these tests.
Therefore, the requested information for a table of acceptance criteria and reported device performance, sample sizes, ground truth establishment, adjudication methods, or MRMC/standalone study results cannot be extracted from this document. The document focuses on demonstrating substantial equivalence to existing legally marketed devices, rather than establishing primary performance metrics through a clinical or non-clinical study with defined acceptance criteria.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health and Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
June 30, 2023
Finemedix Co., Ltd. % Priscilla Chung Regulatory Affairs Consultant LK Consulting Group USA. Inc. 18881 Von Karman Ave STE 160 Irvine, CA 92612
K231267 Re:
Trade/Device Name: ClearTip Regulation Number: 21 CFR 876.1075 Regulation Name: Gastroenterology-urology biopsy instrument Regulatory Class: Class II Product Code: FCG Dated: April 28, 2023 Received: May 2, 2023
Dear Priscilla Chung:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any
{1}------------------------------------------------
Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medicaldevice-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Shanil P. Haugen -S
Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K231267
Device Name ClearTip
Indications for Use (Describe)
The Clear Tip is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum).
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
K231267 Page 1 of 4
510(K) SUMMARY
(K231267)
June 8, 2023
1. Submitted by:
FINEMEDIX Co., Ltd. 140-9, Yuram-ro, Dong-gu, Daegu, 41059 Republic of Korea Tel : 82-53-741-8388, Fax : 82-53-741-8168
2. US Agent/ Official Correspondent:
Priscilla Chung
LK Consulting Group USA, Inc. 18881 Von Karman Ave STE 160 Irvine, CA 92612 Fax: 714.409.3357 Tel: 714.202.5789 Email: juhee.c@LKconsultingGroup.com
3. Device Name:
| - Trade Name | : ClearTip |
|---|---|
| - Classification | : Class II |
| - Classification Name | : Biopsy Needle |
| - Product Code | : FCG |
| - Regulation Number | : 876.1075 |
| - Review Panel | : Gastroenterology/Urology |
4. Predicate Device:
- Primary Predicate Device: SonoTip Pro and Pro Flex EBUS-TBNA Needle System (K133763) by Medi-Globe Corporation
- Reference Predicate Device: Clear-Tip EUS-FNA (K180363) by FINEMEDIX Co., Ltd.
{4}------------------------------------------------
5 Device Description:
The ClearTip is a manually operated endoscopic instrument intended to obtain tissue specimens of gastrointestinal tract (=digestive tract) and tracheobronchial tree.
The subject device mainly consists of a handle unit with an insertion part, a syringe, a stopcock, and a connector. This device passes through a working channel of an endoscope, and the average contact time with the submucosal or external lesions of a gastrointestinal tract or a tracheobronchial tree is less than 1 hour. This device is supplied sterile for single-patient use and shall be not reused or resterilized.
6 Indications for Use Statement
The ClearTip is intended for Ultrasonically Guided Fine Needle Aspiration, (FNA) of submucosal and extraluminal lesions of the Tracheobronchial Tree and Gastrointestinal Tract, (e.g., lymph nodes, abnormal tissue in the mediastinum).
Substantial Equivalence Discussion: 7
7.1.Comparison Chart
| Subject Device | Primary Predicate | Reference Device | |
|---|---|---|---|
| Manufacturer | FINEMEDIX Co., Ltd. | Medi-Globe Corporation | FINEMEDIX Co., Ltd. |
| Device Name | ClearTip | SonoTip Pro and Pro FlexEBUS-TBNA NeedleSystem | Clear-Tip EUS-FNA |
| 510(k) Number | K231267 | K133763 | K180363 |
| DeviceClassification Name | Gastroenterology-urologyBiopsy instrument | Gastroenterology-Urology BiopsyInstrument | Gastroenterology-urologyBiopsy instrument |
| Product Code | FCG | FCG | FCG |
| Regulation Number | 21 CFR 876.1075 | 21 CFR 876.1075 | 21 CFR 876.01075 |
| Indications for Use | The ClearTip is intendedfor Ultrasonically GuidedFine Needle Aspiration,(FNA) of submucosal andextraluminal lesions ofthe TracheobronchialTree and GastrointestinalTract, (e.g., lymph nodes,abnormal tissue in themediastinum). | The SonoTip Pro and ProFlex - TBNA NeedleSystem is intended forUltrasonically GuidedFine Needle Aspiration,(FNA) of submucosaland extraluminal lesionsof the TracheobronchialTree and GastrointestinalTract, (e.g., lymph nodes,abnormal tissue in themediastinum). | The Clear-Tip EUS-FNAis used with an ultrasoundendoscope for fine needlebiopsy of submucosallesions, mediastinalmasses, lymph nodes andintraperitoneal masseswithin or adjacent to thegastrointestinal tract. |
| Needle Gauge | 22 Gauge | 22 Gauge | 19,22,25 Gauge |
| Needle Material | Nitinol | Stainless Steel / Nitinol | Stainless Steel |
| Needle lengthAdjustment range | 0~5 cm | 0~4 cm | 0~8cm |
| Stylet Material | Nitinol | Nitinol | Nitinol |
{5}------------------------------------------------
| Sheath length | 738.5 mm | 730 mm | 1,507 mm |
|---|---|---|---|
| Sheath Material | PEEK, PTFE | PVDF | PEEK |
| Sheath lengthAdjustment range | 0~3cm | 0~4cm | 0~5cm |
| Accessory ChannelDiameter | Minimum AccessoryChannel Diameter(2.0 mm) | Minimum AccessoryChannel Diameter(2.0 mm) | Minimum AccessoryChannel Diameter(2.0 mm) |
| EndoscopeCompatibility(Use with connector) | 1) Olympus, 2) Pentax | 1) Olympus, 2) Pentax | 1) Olympus |
| Use with a Syringeand stopcock | Yes | Yes | Yes |
| Principle ofOperation | Manual (sampling usingaspiration) | Manual (sampling usingaspiration) | Manual (sampling usingaspiration) |
| Shelf life | 3 Years | 5 Years | 3 Years |
| Sterility | Ethylene oxide(EO) | Ethylene oxide(EO) | Ethylene oxide(EO) |
| Single use | Yes | Yes | Yes |
7.2. Substantial Equivalence Discussion
The subject device is substantially equivalent to the primary predicate devices in the indications for use, needle gauge, needle material, accessory channel diameter, endoscope compatibility, use with a syringe and stopcock, principle of operation, sterility, and single use.
The differences between the subject device and the primary predicate device are as below:
-Needle Length Adjustment Range: The maximum needle length of the subject device is 5 cm, and the predicate device is 4 cm. The difference of 1 cm between the two devices does not affect safety and effectiveness during biopsy. It is just an option for the operator to adjust the length of the needle in consideration of the surgical area (position and depth of the tissue to be biopsied).
-Sheath Length: The sheath length of the subject device is 738.5 mm, and the predicate device is 730 mm. The difference of 8.5 mm does not affect safety and effectiveness during biopsy since the physician can control the length as needed.
-Sheath Material: The raw material of the sheath of the subject device is PEEK & PTFE, and the predicate device is PVDF. We performed biocompatibility testing on the subject device, and based on the test result, we conclude that the subject device is biocompatible and substantially equivalent to the predicate devices.
-Shelf Life: The shelf life of the subject device is 3 years, and the shelf life of the predicate device is 5 years. We performed shelf-life testing, and based on the test result, we conclude that the subject device has 3-year shelf life.
{6}------------------------------------------------
We are presenting Clear-Tip EUS-FNA (K180363) made by our company as a reference device. It shares similarities with the subject device in terms of indications for use statement, needle gauge, stylet material, accessory channel diameter, endoscope compatibility, use with a syringe and stopcock, principle of operation, sterility, and single use.
The differences between the subject device and the reference predicate device are as follows:
- Claim: The reference device does not include a claim on the Tracheobronchial Tree.
- Sheath Length: The sheath of the subject device is shorter than that of the reference device. The shortened length of the subject device is for user convenience, especially when using the device on the Tracheobronchial Tree.
- This reference device is presented to leverage some of the test items, such as EO sterilization validation, Real-Time Shelf-Life, and Shipping Validation, for the subject device. We have also referenced the test parameters, test method, and P/F criteria from this 510k.
8. Non-clinical Tests
The following tests were performed on the subject device and the test results support that the subject device is substantially equivalent to the predicate devices.
- Sterilization Validation Test ●
- Shelf-Life Test ●
- Appearance
- Dimensions ●
- Operability ●
- Elasticity ●
- Bending Strength ●
- Pull-out ●
- Tensile Force ●
- Biocompatibility Tests ●
9. Conclusion:
Based on the information provided herein and the test results, we conclude that the subject device is substantially equivalent to its predicate device.
§ 876.1075 Gastroenterology-urology biopsy instrument.
(a)
Identification. A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification. (1) Class II (performance standards).(2) Class I for the biopsy forceps cover and the non-electric biopsy forceps. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.